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Objectives. We sought to evaluate the prognostic significance of
cardiac troponin T (TnT) serum levels after noncardiac surgery.
Background. Cardiac TnT has been found to be a marker for
myocardial injury, but elevations of TnT are common in patients
undergoing noncardiac surgery without clinical evidence of severe
ischemia.
Methods. We studied 772 patients who underwent major non-
cardiac procedures and did not have major cardiovascular com-
plications during their inpatient course. Total serum creatine
kinase (CK) and cardiac TnT were measured according to a
protocol that included sampling in the recovery room and during
the next 2 days. A 6-month follow-up interview was performed for
722 (94%) of the patients.
Results. Elevated cardiac TnT and CK-MB results were de-
tected for 92 (12%) and 211 (27%) patients, respectively. During
the follow-up period, there were 19 (2.5%) major cardiac compli-
cations, including 14 cardiac deaths, 3 nonfatal myocardial in-
farctions and 2 admissions for unstable angina. Compared with
patients with cardiac TnT values <0.1 ng/ml, patients with
elevated TnT had a relative risk for cardiac events of 5.4 (95%
confidence interval: 2.2 to 13, p 5 0.001), whereas CK-MB was not
correlated with postdischarge cardiac events. In multivariate
logistic regression analysis adjusting for preoperative clinical and
CK-MB data, a cardiac TnT value >0.1 ng/ml was an independent
correlate of cardiac events (adjusted odds ratio 4.6, p < 0.05).
This correlation was a function of the relation of elevated TnT levels
with postoperative in-hospital congestive heart failure and new
sustained arrhythmias, suggesting that elevated postoperative TnT
levels detected myocardial ischemia during these clinical events.
Conclusions. We conclude that an abnormal TnT level in
patients undergoing noncardiac surgery may be a useful marker
of ischemic disease and a predictor of 6-month prognosis.
(J Am Coll Cardiol 1997;29:1241–5)
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Detection of myocardial injury after noncardiac surgery is
complicated by the high prevalence of electrocardiographic
(ECG) abnormalities (1) and the high false positive rate of
creatine kinase (CK)-MB (2) in this setting. Some data have
suggested that newer markers of myocardial injury, including
cardiac troponin I (3) and T (4,5), might improve management
of patients by identifying those who were having or were at risk
for cardiac complications. We (6) have reported that, in
patients undergoing major noncardiac surgery, cardiac tropo-
nin T (TnT) has a high sensitivity for acute myocardial
infarction and, among patients without infarction, has a higher
correlation with other cardiac complications than does CK-
MB. However, in that cohort, many patients without clinical
complications had elevated cardiac TnT values, raising the
question of whether these values were false positive results or
evidence of subclinical myocardial injury.
To address this issue, we have collected 6-month follow-up
data including cardiac outcomes on a subcohort of patients
from this previous investigation. The results have implications
for the use and interpretation of serum markers after noncar-
diac surgery.
Methods
Patients. All patients aged $50 years who underwent
major noncardiac procedures at Brigham and Women’s Hos-
pital from December 5, 1991 to May 31, 1994 were eligible for
the study. Major noncardiac procedures were defined as those
with an expected length of stay $2 days. The clinical and
cardiac marker data collection protocol is described in a
previous report (6) and was approved by the Brigham and
Women’s Hospital Human Research Committee.
In brief, patients who provided signed informed consent to
the full study protocol underwent a preoperative history and
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physical examination by study personnel using a structured
data form. The protocol included postoperative sampling of
CK and, if total CK levels were elevated, CK-MB, at the
following times: 1) immediately postoperatively in the recovery
room, 2) at 8 PM on the evening of the day of operation, and 3)
on the next 2 mornings. For patients who could not be
approached before the operation for informed consent (22%
of the study population), data were included in this report if
they underwent postoperative serial cardiac marker sampling
(standard practice is measurement of CK and CK-MB every
8 h) and gave informed consent for 6-month follow-up.
Cardiac TnT was measured by using excess serum remain-
ing after performance of CK and CK-MB samples that were
ordered either as part of routine care or as part of the study
protocol. The mean and median number of cardiac TnT
measurements per patient were 3.4 and 3, respectively.
Patients were included in this report only if they had at least
two determinations of markers for myocardial injury. Total CK
was assayed throughout this study on the ACA discrete clinical
analyzer (Du Pont). The upper limits of the reference interval
are 218 U/liter and 266 U/liter for women and men, respec-
tively. CK-MB was measured from the beginning of the study
to July 30, 1993 with use of a Du Pont ACA ion exchange
chromatography and immunoinhibition assay that measures
the activity of CK-MB (reference interval 0 to 8 U/liter).
Beginning on August 1, 1993, a mass assay for CK-MB,
utilizing a monoclonal antibody, was performed on the Stratus
instrument (Baxter Diagnostics). The upper limit of the refer-
ence interval is 5 ng/ml. Troponin T was measured by an
immunoassay procedure that uses complementary monoclonal
antibodies (7). Analysis was performed on the ES-300 (Boehr-
inger Mannheim Corporation) and the upper limit of the
reference interval is 0.1 ng/ml. The assay is specific for cardiac
troponin T (8–12).
The presence or absence of cardiac complications postop-
eratively was classified by reviewers who used clinical informa-
tion recorded on structured data forms; these reviewers had no
knowledge of cardiac TnT data. The diagnosis of myocardial
infarction was made on the basis of CK-MB levels and ECG
findings. When the ion exchange chromatography assay was
used to assay CK-MB, acute myocardial infarction was diag-
nosed if 1) the peak CK-MB was .5% of an elevated total CK,
or 2) the peak CK-MB was .3% of an elevated total CK in the
presence of ECG changes consistent with ischemia or infarc-
tion. When the CK-MB mass assay was used, acute myocardial
infarction was diagnosed if peak CK-MB levels exceeded the
normal range (0 to 5 ng/ml) and the ratio of CK-MB to total
CK exceeded 0.0278, a threshold ratio that was estimated to be
comparable to a 0.05 threshold with the ion exchange chroma-
tography assay for CK-MB based on the normal ranges for
CK-MB with the two assays. If the postoperative ECG had
changes consistent with ischemia, acute myocardial infarction
was diagnosed if peak CK-MB was elevated and the ratio of
CK-MB to total CK exceeded 0.0167.
Major cardiac complications were defined as the occurrence
of myocardial infarction or any of the following: 1) pulmonary
edema, 2) primary cardiac arrest, 3) ventricular fibrillation, or
4) complete heart block requiring therapeutic intervention to
maintain normal hemodynamic function. Criteria for diagnos-
ing pulmonary edema included a blinded interpretation of
chest X-ray films by a radiologist. Less severe postoperative
cardiac complications that were included in the analysis (con-
gestive heart failure, chest pain with ECG changes and new
sustained atrial or ventricular arrhythmia) were defined as
present if noted by clinicians in the medical record.
Follow-up data collection. To improve the completeness of
follow-up, only residents of Massachusetts were included in
this analysis. From the original cohort of 1,177 patients, 34
were excluded because they had major cardiac complications
before discharge from the hospital. Of the remaining 1,143
patients, 371 (32%) were excluded because they lived outside
Massachusetts. Follow-up by telephone $6 months after dis-
charge was performed successfully for 722 (94%) of the
remaining 772 patients. A search for death certificates at
the Massachusetts Bureau of Vital Statistics was performed
for the 6% of patients who could not be contacted.
Nineteen patients were classified as having a postdischarge
cardiac complication on the basis of these interviews and
review of medical records. In 18 of these 19, the outcome was
identified by interview of either the patient or a relative. The
outcome of the other patient (a nonfatal myocardial infarc-
tion) was identified through medical record review. All 14
patients who were reported during interviews to have died
were also recorded as having died in the Massachusetts
Registry of Deaths; hence, the absence of a death certificate
for the patients who could not be contacted for follow-up can
be considered evidence of probable survival.
Specific cause of death was determined through analysis of
the death certificates, hospital charts and autopsy reports. The
deaths were classified as cardiovascular or noncardiovascular
independently by two researchers who had no knowledge of
TnT levels. These reviewers agreed in 11 of the 14 cases
initially and achieved consensus on the remaining 3 cases after
discussion. For patients who were admitted to the hospital
postoperatively, medical records were reviewed to determine
whether the cause of readmission was acute myocardial infarc-
tion, unstable angina or another condition.
Analysis of data. Univariate correlations between clinical
characteristics and abnormal TnT and CK-MB levels were
calculated by using a chi-square test or a Fisher exact test.
Relative risk (RR) for postdischarge cardiac complications was
Abbreviations and Acronyms
CK 5 creatine kinase
CK-MB 5 creatine kinase, MB isoenzyme
ECG 5 electrocardiogram, electrocardiographic
OR 5 odds ratio
PTCA 5 percutaneous transluminal coronary angioplasty
RR 5 relative risk
TnT 5 cardiac troponin T
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calculated for these markers and for other clinical character-
istics. Multivariate logistic regression analysis was used to
assess the independent correlation of peak cardiac marker
levels with postdischarge cardiac complication rates after
adjusting for other clinical correlates of complications. Poten-
tial confounders considered in these models were variables
with univariate correlations with postdischarge complications
with a p value ,0.2.
Results
Of the 772 patients without postoperative major cardiac
complications during their inpatient course, 92 (12%) had
elevated (.0.1 ng/ml) cardiac TnT levels postoperatively.
Compared with patients who had normal TnT levels, those
who had abnormal levels were older and were more likely to be
male, to have diabetes or hypertension and to be current
smokers of cigarettes (Table 1). Patients with elevated TnT
levels were also more likely to report during their preoperative
evaluation that they had a history of chest pain, prior myocar-
dial infarction, congestive heart failure, prior coronary angiog-
raphy and prior coronary artery bypass graft surgery. Abnor-
mal levels of cardiac TnT were significantly less common
among patients who underwent orthopedic procedures and
were more common among patients who underwent thoracic
and vascular procedures. Patients with elevated cardiac TnT
were more likely to have elevated peak CK-MB levels postop-
eratively. Although none of the patients in this cohort had
major postoperative cardiac complications, the patients with
elevated cardiac troponin T levels had higher rates of postop-
erative congestive heart failure and new arrhythmias (Table 1).
Chest pain with ECG changes was uncommon in patients with
or without abnormal cardiac troponin T levels.
Postdischarge course. Of the 772 study subjects, 19 (2.5%)
had an adverse postdischarge cardiac outcome during the
6-month follow-up period, including cardiac death in 14,
nonfatal myocardial infarction in 3 and admission for unstable
angina in 2. Of the patients who had an adverse outcome, 8
(42%) had elevated peak TnT levels, compared with 84 (11%)
of the 753 patients without postdischarge complications (p ,
0.05) (Table 2). Therefore, an abnormal TnT level had a
positive predictive value of 8 (9%) of 92 and an RR of 5.4.
Abnormal CK-MB values were not significantly correlated with
subsequent complications. Other significant (p , 0.05) corre-
lates of complications included male gender, history of diabe-
tes, history of ischemic chest pain, congestive heart failure,
prior coronary arteriography or revascularization and postop-
erative congestive heart failure or sustained new arrhythmias.
In stepwise and global multivariate logistic regression anal-
yses that included just preoperative clinical data and CK-MB
data, an elevated cardiac TnT level remained an independent
predictor of adverse cardiac outcome. In a model adjusting for
CK-MB, type of operation, age, gender, previous cardiac
history, smoking history, medications and history of diabetes,
the adjusted odds ratio (OR) for complications associated with
an elevated cardiac TnT level was 4.6 (p , 0.05). When data on
the occurrence of postoperative congestive heart failure and
new sustained arrhythmias were added to multivariate models,
cardiac troponin T no longer was a significant independent
correlate of postdischarge complications (OR 2.25, p 5 0.32).
Data presented in Table 3 show that elevated cardiac TnT
levels were associated with an increased risk for complications
in the low risk subgroups of patients undergoing nonvascular
surgery (RR 7.6, p , 0.001) and patients without preoperative
congestive heart failure (RR 4.1, p 5 0.06).
Discussion
In this report, we describe 6-month follow-up data for
patients who had elevated cardiac TnT levels after noncardiac
surgery in the absence of clinical evidence of major cardiac
complications. In both univariate analyses and after adjusting
for preoperative clinical correlates of complications, cardiac
TnT was an independent correlate of complications. This
Table 1. Description of Patients
Characteristic
Cardiac Troponin T Level
Abnormal
(n 5 92
[100%])
Normal
(n 5 680
[100%])
p
Value
Age $60 yr 82 (89%) 528 (78%) 0.01
Male 70 (76%) 326 (48%) 0.001
White 83 (90%) 633 (93%) 0.32
Diabetic 21 (23%) 86 (13%) 0.008
Hypertension 59 (65%) 296 (44%) 0.001
Current smoking 19 (21%) 123 (18%) 0.04
Hypercholesterolemia 21 (26%) 167 (26%) 0.98
Chest pain presumed
to be ischemic
19 (21%) 70 (10%) 0.004
Previous MI 27 (29%) 103 (15%) 0.001
CHF 14 (15%) 41 (6%) 0.001
Prior coronary
angiography
28 (32%) 101 (16%) 0.001
Prior CABG 17 (20%) 54 (8%) 0.001
Prior PTCA 1 (1%) 13 (2%) 1.00
Aspirin use 17 (18%) 154 (23%) 0.37
Beta-blocker use 21 (23%) 132 (19%) 0.44
Type of surgery
General 8 (9%) 138 (20%) 0.008
Gynecologic 0 (0%) 22 (3%) 0.08
Neurologic 1 (1%) 24 (4%) 0.214
Orthopedic 20 (22%) 251 (37%) 0.004
Thoracic 23 (25%) 67 (10%) 0.001
Urologic 10 (11%) 46 (7%) 0.154
Vascular 30 (33%) 132 (19%) 0.004
Postoperative findings
CHF 11 (12%) 11 (2%) 0.001
Chest pain with
ECG changes
1 (1%) 2 (0.3%) 0.3
New arrhythmia 36 (39%) 55 (8%) 0.001
Abnormal CK-MB 62 (67%) 149 (22%) 0.001
CABG 5 coronary artery bypass graft surgery; CHF 5 congestive heart
failure; CK-MB 5 creatine kinase MB isoenzyme level; ECG 5 electrocardio-
graphic; MI 5 myocardial infarction; PTCA 5 percutaneous transluminal
coronary angioplasty.
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Table 2. Correlates for Cardiac Complications Within 6 Months After Discharge
Predictor
Patients
RR (95% CI) p ValueTotal With Complications
Cardiac troponin T
Abnormal* 92 8 (8.7%) 5.4 (2.2–13) 0.001
Normal 680 11 (1.6%)
CK-MB
Abnormal* 211 6 (2.8%) 1.2 (0.5–3.2) 0.67
Normal 561 13 (2.3%)
Age
$60 yr 610 17 (2.8%) 2.3 (0.5–9.7) 0.39
,60 yr 162 2 (1.2%)
Gender
Male 396 16 (4.0%) 5.1 (1.5–17.2) 0.004
Female 376 3 (0.8%)
Race
Nonwhite 56 3 (5.4%) 2.4 (0.7–8.0) 0.15
White 716 16 (2.2%)
Vascular surgery
Yes 161 6 (3.7%) 1.8 (0.7–4.5) 0.24
No 611 13 (2.1%)
Medical history of
Diabetes
Yes 107 7 (6.5%) 3.6 (1.5–9.0) 0.003
No 665 12 (1.8%)
Hypertension
Yes 355 7 (2.0%) 0.7 (0.3–1.9) 0.52
No 410 11 (2.7%)
Smoking
Current 142 4 (2.8%) 1.2 (0.4–3.5) 0.76
Never or past 630 15 (2.4%)
Hypercholesterolemia
Yes 188 6 (3.2%) 1.4 (0.5–3.8) 0.46
No 541 12 (2.2%)
Preoperative history of
Ischemic chest pain
Yes 89 6 (6.7%) 3.5 (1.4–9.1) 0.006
No 683 13 (1.9%)
Myocardial infarction
Yes 130 6 (4.6%) 2.3 (0.9–5.9) 0.08
No 642 13 (2.0%)
Congestive heart failure
Yes 55 10 (18.2%) 14.5 (6.1–34.1) 0.001
No 717 9 (1.3%)
Prior coronary angiography
Yes 129 8 (6.2%) 3.4 (1.4–8.3) 0.004
No 607 11 (1.8%)
Prior CABG
Yes 71 7 (9.9%) 5.4 (2.2–13.4) 0.001
No 663 12 (1.8%)
Prior PTCA
Yes 14 2 (14.3%) 6.0 (1.5–23.7) 0.048
No 719 17 (2.4%)
Use of aspirin
Yes 171 6 (3.5%) 1.6 (0.6–4.2) 0.32
No 601 13 (2.2%)
Use of beta-blocker
Yes 153 7 (4.6%) 2.4 (0.9–5.9) 0.059
No 619 12 (1.9%)
Postoperative complications
Congestive heart failure
Yes 17 5 (22.7%) 12 (4.1–31) 0.001
No 736 14 (1.9%)
Chest pain with ECG changes
Yes 3 0 (0%) — (—) 1.0
No 750 19 (2.5%)
New arrhythmia
Yes 82 9 (9.9%) 6.7 (2.8–16) 0.001
No 671 10 (1.5%)
*See Methods for definition of abnormal and normal values. CI 5 confidence interval; RR 5 relative risk; other
abbreviations as in Table 1.
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correlation became nonsignificant when data on postoperative
congestive heart failure and new sustained arrhythmias were
introduced into multivariate analyses.
These data are consistent with the hypothesis that elevated
TnT levels in these patients may reflect degrees of myocardial
ischemia that were not sufficient to cause CK-MB abnormali-
ties or to lead to chest pain and ECG abnormalities that were
detected through routine clinical care. The findings indicate
that postoperative cardiovascular events such as heart failure
and arrhythmias may often have an ischemic pathophysiology
and that cardiac TnT may enhance identification of high risk
patients.
These findings are consistent with and extend previous
research on cardiac TnT as a marker of myocardial injury.
Other studies (13–17) have shown that, in patients with
unstable angina, TnT elevations identify patients with an
increased risk for cardiac complications. However, in these
studies, many patients with elevated cardiac TnT levels did not
have complications. These findings have raised the question of
whether longer-term follow-up might also identify these pa-
tients with false positive results as having an increased risk for
cardiac complications.
Our data must be interpreted in the context of the study
design. Detection of clinical complications after the noncardiac
operations was dependent on the notes recorded by the
responsible physicians as part of routine care. Physicians were
not provided with cardiac TnT results, and patients who had
elevated TnT levels might have had a higher rate of diagnoses
of cardiac complications during their hospital stay had they
undergone a more systematic and comprehensive monitoring
protocol. In addition, the sampling protocol of TnT and
CK-MB may have missed abnormal values that would have led
to classification of more patients as having had acute myocar-
dial infarction. Finally, even though 94% of patients were
successfully contacted for interviews, clinical outcomes may
have been missed by this follow-up mechanism.
Nevertheless, the findings suggest that an abnormal TnT
serum level in the perioperative period may be a useful
predictor for major cardiac outcomes during the subsequent 6
months. This association may be due to a greater sensitivity for
perioperative cardiac injury than is possible with CK-MB.
These data indicate that elevated TnT levels in patients
without clinical evidence for ischemia should not be dismissed
as false positive results and that these patients may warrant
further cardiac evaluation.
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No history of CHF
TnT 4.1 (1.0–16.1) 0.06
CK-MB 1.3 (0.3–5.3) 0.71
History of CHF
TnT 2.9 (1.0–8.6) 0.05
CK-MB 1.1 (0.3–3.9) 1.0
Male
TnT 3.6 (1.4–9.4) 0.005
CK-MB 0.9 (0.3–2.5) 1.0
Female
TnT 8.0 (0.8–85) 0.17
CK-MB 1.9 (0.2–21) 0.5
Vascular surgery
TnT 2.2 (0.4–11.4) 0.3
CK-MB 0.8 (0.1–6.2) 1.0
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TnT 5 cardiac troponin T; other abbreviations as in Tables 1 and 2.
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